{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:17:55Z","timestamp":1790162275387,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,1,6]],"date-time":"2009-01-06T00:00:00Z","timestamp":1231200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:p>\n                    <jats:bold>OBJECTIVES:<\/jats:bold>\n                    To clarify the association between anticholinergic drugs and apolipoprotein E \u025b4 allele carrier status (\n                    <jats:italic>APOE4<\/jats:italic>\n                    ) and cognitive dysfunction.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>DESIGN:<\/jats:bold>\n                    Cross\u2010sectional analyses of current drug use and cognitive functioning according to the baseline assessments of the Drugs and Evidence\u2010Based Medicine in the Elderly Study.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>SETTING:<\/jats:bold>\n                    Helsinki, Finland.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>PARTICIPANTS:<\/jats:bold>\n                    Four hundred community\u2010dwelling people aged 75 to 90 without clinical dementia but with a history of stable atherosclerotic disease.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>MEASUREMENTS:<\/jats:bold>\n                    Cognitive function according to the Mini\u2010Mental State Examination (MMSE) and Clinical Dementia Rating Scale (CDR). Participants' use of anticholinergic drugs was estimated using definitions from previous scientific literature.\n                    <jats:italic>APOE<\/jats:italic>\n                    alleles determined from peripheral blood leukocyte deoxyribonucleic acid using standard polymerase chain reaction\u2013based methods.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS:<\/jats:bold>\n                    There was an association between anticholinergic drugs and lower MMSE scores (\n                    <jats:italic>P<\/jats:italic>\n                    for trend &lt;.001). The higher the number of anticholinergic drugs, the lower the MMSE score. Subjects with the\n                    <jats:italic>APOE4<\/jats:italic>\n                    allele and using drugs with anticholinergic properties had the lowest median MMSE score (26), whereas those without the\n                    <jats:italic>APOE4<\/jats:italic>\n                    allele and not using drugs with anticholinergic properties had the highest median MMSE score (28). When adjusted for age, sex, and education, the difference between the groups remained significant. The finding was similar for CDR scores.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSION:<\/jats:bold>\n                    Use of drugs with anticholinergic properties was associated with lower cognitive function irrespective of\n                    <jats:italic>APOE4<\/jats:italic>\n                    carrier status. Having lower cognitive function as a group,\n                    <jats:italic>APOE4<\/jats:italic>\n                    carriers may be more vulnerable to this undesirable effect, but a follow\u2010up study is needed to demonstrate this.\n                  <\/jats:p>","DOI":"10.1111\/j.1532-5415.2008.02129.x","type":"journal-article","created":{"date-parts":[[2009,1,6]],"date-time":"2009-01-06T16:39:15Z","timestamp":1231259955000},"page":"427-431","source":"Crossref","is-referenced-by-count":32,"title":["Association Between Anticholinergic Drugs and Apolipoprotein E \u025b4 Allele and Poorer Cognitive Function in Older Cardiovascular Patients: A Cross\u2010Sectional Study"],"prefix":"10.1111","volume":"57","author":[{"given":"Juho","family":"Uusvaara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisu H.","family":"Pitkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pentti J.","family":"Tienari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannu","family":"Kautiainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reijo S.","family":"Tilvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo E.","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,3,3]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"455","article-title":"Non\u2010degenerative mild cognitive impairment in elderly people and of anticholinergic drugs","volume":"332","author":"Ancelin M","year":"2006","journal-title":"Longitudinal cohort study"},{"key":"e_1_2_6_3_2","first-page":"143","article-title":"Drugs with anticholinergic properties and cognitive performance in the elderly","volume":"59","author":"Lechevallier\u2010Michel N","year":"2004","journal-title":"Results from the PAQUID Study"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.2.198"},{"key":"e_1_2_6_5_2","first-page":"389","article-title":"Drug use patterns in a very elderly population","volume":"17","author":"Giron MST","year":"1999","journal-title":"A seven-year review"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200118020-00007"},{"key":"e_1_2_6_7_2","first-page":"1393","article-title":"Anticholinergic effects of drugs commonly prescribed for the elderly","volume":"149","author":"Tune L","year":"1992","journal-title":"Potential means for assessing risk of delirium"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.14.7.1084"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1997.tb48471.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-3-200208060-00006"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2004.05.003"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00408.2004"},{"key":"e_1_2_6_13_2","first-page":"403","article-title":"Increased anticholinergic challenge\u2010induced memory impairment associated with the APOE\u2010epsilon4 allele in the elderly","volume":"29","author":"Pomara N","year":"2004","journal-title":"A controlled pilot study"},{"key":"e_1_2_6_14_2","first-page":"945","article-title":"Multifactorial cardiovascular prevention in patients aged 75 and older","volume":"142","author":"Strandberg TE","year":"2001","journal-title":"Randomized controlled trial. Drugs and Evidence Based Treatment in the Elderly (DEBATE) Study"},{"key":"e_1_2_6_15_2","first-page":"1216","article-title":"Possibilities of multifactorial cardiovascular disease prevention in patients aged 75 and older","volume":"24","author":"Strandberg TE","year":"2003","journal-title":"A randomized, controlled trial. Drugs and Evidence-Based Treatment in the Elderly (DEBATE) Study"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.140.6.566"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92823-K"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/014107680009300903"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.4065\/79.1.122"},{"key":"e_1_2_6_21_2","first-page":"1531","article-title":"Explicit criteria for determining potentially inappropriate medication use by the elderly","volume":"157","author":"Beers MH.","year":"1997","journal-title":"An update"},{"key":"e_1_2_6_22_2","first-page":"841","article-title":"Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder","volume":"326","author":"Herbison P","year":"2003","journal-title":"Systematic review"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2210-5-8"},{"key":"e_1_2_6_24_2","first-page":"462","article-title":"An overview of overactive bladder and its pharmacological management with a focus on anticholinergic drugs","volume":"31","author":"DeMaagd G","year":"2006","journal-title":"P&T"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.00537.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2003000200010"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.18773\/austprescr.2003.026","article-title":"Anticholinergic bronchodilatators","volume":"26","author":"Seale P.","year":"2003","journal-title":"Aust Prescr"},{"key":"e_1_2_6_28_2","first-page":"189","article-title":"The cholinergic system in schizophrenia reconsidered","volume":"21","author":"Tandon R","year":"1999","journal-title":"Anticholinergic modulation of sleep and symptom profiles"},{"key":"e_1_2_6_29_2","first-page":"325","article-title":"Metoclopramide causes airway smooth muscle relaxation through inhibition of muscarinic M3 receptor in the rat trachea","volume":"98","author":"Saito M","year":"2004","journal-title":"Anesth Analg"},{"key":"e_1_2_6_30_2","first-page":"27","article-title":"The pharmacokinetics and effects of prochlorperazine in elderly female volunteers","volume":"21","author":"Isah A","year":"1991","journal-title":"Oxford J"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0022-3565(24)29325-3","article-title":"Inhibition by tramadol of muscarinic receptor\u2010induced responses in cultured adrenal medullary cells and in Xenopus laevis oocytes","volume":"299","author":"Shiraishi M","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.26.12260"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2005.12.016"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.4.985"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.134"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511093331902"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199909)46:3<382::AID-ANA14>3.0.CO;2-5"},{"key":"e_1_2_6_38_2","first-page":"589","article-title":"Cerebral amyloid angiopathy in a 95+ cohort","volume":"31","author":"Tanskanen M","year":"2005","journal-title":"Complement activation and ApoE genotype"},{"key":"e_1_2_6_39_2","first-page":"487","article-title":"Vascular changes in human senile brain","volume":"20","author":"Ravens J.","year":"1978","journal-title":"Adv Neurol"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1824"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-002-1028-6"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1532-5415.2008.02129.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1532-5415.2008.02129.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:59:27Z","timestamp":1762181967000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1532-5415.2008.02129.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1111\/j.1532-5415.2008.02129.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1532-5415.2008.02129.x","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}